Description
Indication & Scope
Bevifibatide Citrate Injection treats acute coronary syndrome (ACS).
- Mechanism: Synthetic glycoprotein IIb/IIIa receptor antagonist, blocks platelet final common aggregation pathway to inhibit platelet cross-linking, reduce thrombus formation in coronary arteries.
- Drug class: GP IIb/IIIa inhibitor, injectable antiplatelet cardiovascular therapeutic agent.
- Clinical use: Peri-procedural antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI).
| Generic Name | Bevifibatide Citrate Injection |
| Brand Name | BETAGRIN |
| Ingredient | Bevifibatide Citrate Injection |
| Dosage Form | Injection |
| Package | 10ml: 20mg*8 vials/box |
| Conditions Treated | Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction) |
| Taboos | 1. Severe hypersensitivity to bevifibatide citrate or excipients
2. Active pathological bleeding or high bleeding risk lesions 3. History of stroke within 30 days, hemorrhagic stroke history 4. Severe uncontrolled hypertension |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store vials at 2°C to 25°C, protected from light, do not freeze the solution. |
| Manufacturer | BaiAoTai Biopharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20240030 |
| Approval Date | Jun 25, 2024 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 180 mcg/kg IV push followed by continuous infusion at 2 mcg/kg/min for up to 72 hours or until PCI completion.
Time: IV bolus administered rapidly, continuous infusion runs non-stop throughout ACS management and PCI procedure.
Instructions for use:
1. Monitor activated clotting time and bleeding signs continuously during infusion.
2. Discontinue infusion immediately if major bleeding occurs.
3. Do not administer intramuscular injections during treatment.
4. Use dedicated IV line to avoid mixing with other medications.
Interaction:
1. Concurrent aspirin, P2Y12 inhibitors and anticoagulants significantly increase major bleeding risk.
2. Thrombolytic agents are contraindicated for co-administration.
Side effects:
1. Common: Minor bleeding (ecchymosis, oozing at access sites), hypotension, nausea.
2. Severe: Severe intracranial hemorrhage, major gastrointestinal bleeding, thrombocytopenia, anaphylaxis.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the primary indication of Bevifibatide Citrate Injection?
Treatment of acute coronary syndrome in patients undergoing PCI.
What drug class does Bevifibatide Citrate Injection belong to?
GP IIb/IIIa receptor antagonist antiplatelet agent.
What is Bevifibatide Citrate Injection's core mechanism?
It blocks platelet aggregation pathways to prevent coronary thrombus formation.
What is the most dangerous severe side effect of Bevifibatide Citrate Injection?
Severe intracranial hemorrhage and major gastrointestinal bleeding.
BETAGRIN® | Bevifibatide Citrate Injection | Acute Coronary Syndrome | DengYueRX
INN: Bevifibatide Citrate Injection
Indications: Treatment of acute coronary syndrome (ACS).
Dosage Form: Injection
Strength: 10ml: 20mg
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
